A new era of oncology through artificial intelligence
Open accessThe DOI matches its Crossref record.
Abstract
Patients’ care, from diagnosis to treatment, has radically changed; however, the awareness about the ongoing revolution has not yet spread through the oncology community. To date, due to technical advances, cancer research is producing information at an incredibly rapid pace challenging even the most tech-competent physicians to use these data to significantly improve patient care. An example is the current information about the cancer’s genome: millions of molecular alterations that might impact the growth of cancer cells have been discovered and might also influence the response to treatment. It has been estimated that a physician should read 29 hours per working day in order to stay updated about new medical research. Moreover, every year, the medical literature increases by doubling the amount of information every 3 years. The result is that it is only going to get harder for several generations of oncologists, like me, who have spent hours searching in the literature an answer to a medical question. Several times this ended up in a long process of reading from one article to the next one and possibly missing the answer to the initial problem. There must be a better way to integrate the current knowledge and give to our patients the best possible care. One such solution was born in 1956 with artificial Intelligence or AI. One of the leading AI or cognitive technologies is IBM Watson, which can learn reason and understand the enormous corpus of the literature available to the scientific community. Such technology will help us make connections among all the data needed to answer a complex medical question in a very short time. Moreover, these technologies can ingest all of the published scientific knowledge, including clinical data of every single patient, ending up with evidence-based and personalised treatment options. For example, Watson for Genomics ingests approximately 10 000 scientific articles and 100 new clinical trials every month. In one scenario, the clinician may train Watson with the tumours characteristics, the patients’ comorbidities and also add any specific wishes from the patient, for example, if the patient does not want hair loss. Based on these notions and any national and international guidelines, a cognitive computer will be able to generate a ranked list of therapeutical options, including the evidence. Moreover, it will be possible to adapt the suggestions based on the specific constrains of a country. For example, in India, it can take anywhere from 4 months to 2 years for a new product to enter the country1.EKumar Sharma. N/A. Some new cancer drugs are available in other countries, but not in India.Business Today In, 22 Dec 2013. http://www.businesstoday.in/magazine/features/some-new-cancer-drugs-still-not-available-in-india/story/201095.html.Google Scholar. Finally, such a technology could also evaluate inclusion and exclusion criteria of all possible clinical trials for each patient and find a matching list of studies in which the patient can be included. These capacities and many others have been made possible, thanks to the collaboration between the IBM researchers and the Memorial Sloan Kettering who have also trained Watson on how a decision is made at a tumour board. Recently, at the San Antonio Conference 2016, the results of a double-blind study with 638 patients were presented comparing the decisions made by the tumour board at the Manipal Comprehensive Cancer Center (India) and the ones made by Watson for Oncology. Incredibly, 90% of Watson for Oncology’s recommendations for standard treatment or consideration were concordant with the recommendations of the tumour board.2.THagen. IBM's Watson Achieves High Concordance in Tumor Board Test.OncLive, 9 Dec 2016. http://www.onclive.com/conference-coverage/sabcs-2016/ibms-watson-achieves-high-concordance-in-tumor-board-test.Google Scholar This tumour board was concerning patients with breast cancer and enlightens a great opportunity for big cancer centres where not all patients can be discussed due to time limitations. It is very interesting that the investigators from India, who have been working with Watson, explained how the collaboration between them and Watson was uncomplicated as they entered the electronic patients’ charts and asked Watson for an evaluation of the case. All clinical data, laboratory results and physicians’ notes were analysed. In about 40 s, Watson gave a treatment suggestion as well as the scientific evidence for each suggestion. How long would it take a physician to carefully evaluate the same data without any omission or bias? These results have been met with great enthusiasm, but also fear between physicians: when will we all be able to use such a tool and are we still going to be fundamental for patients? Several cancer centres, mainly in the USA, are already working with these platforms and further developing the capacities of such cognitive computers. Indeed, Watson is very young, growing at
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
The Application of Medical Artificial Intelligence Technology in Rural Areas of Developing Countries
Guo, J., & Li, B. (2018) · Health Equity · doi:10.1089/heq.2018.0037 · Cited by 401
“As such, it is not possible to rely solely on humans to keep up with it.(13) In addition, big data, including EHRs, ‘‘omic’’ data (e.”
BackgroundMethodWang, D., Churchill, E., Maes, P., Fan, X., Shneiderman, B., Shi, Y., & Wang, Q. (2020) · Extended Abstracts of the 2020 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3334480.3381069 · Cited by 271
“For example, IBM Watson Oncology, with some controversy, has proved that it can predict the symptom based on scan image data as well as human doctors [2].”
BackgroundWang, D., Wang, L., Zhang, Z., Wang, D., Zhu, H., Gao, Y., Fan, X., & Tian, F. (2021) · Proceedings of the 2021 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3411764.3445432 · Cited by 209
“These new AI methods, combined with the availability of large clinical datasets, revolutionize CDSS interventions from rule-based approaches toward a more “big data” and numeric-based approach [16, 41, 78].”
BackgroundLin, H., Li, R., Liu, Z., Chen, J., Yang, Y., Chen, H., Lin, Z., Lai, W., Long, E., Wu, X., et al. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.03.001 · Cited by 199
Metadata
- Authors
- Curioni-Fontecedro, A.
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2017
- Volume
- 2
- Issue
- 2
- Pages
- e000198
- ISSN
- 2059-7029 (ISSN-L)
- OpenAlex
- W2613716520
- Cited by
- 48
- References
- 0
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.